TABLE 1.
Subject characteristics and correlations with plasma and CSF visfatin concentrations and the CSF-to-plasma visfatin ratio
| Mean ± SEM | Plasma visfatin | CSF visfatin | CSF-to-plasma visfatin ratio | |
|---|---|---|---|---|
| Age (years) | 53.26 ± 2.58 | 0.23 | −0.36* | −0.34* |
| BMI (kg/m2) | 26.67 ± 0.76 | 0.69† | −0.52† | −0.73† |
| Body weight (kg) | 77.99 ± 2.81 | 0.71† | −0.47‡ | −0.70† |
| Fat mass (kg) | 22.56 ± 1.64 | 0.71† | −0.68† | −0.80† |
| Waist circumference (cm) | 95.11 ± 2.37 | 0.59† | −0.48‡ | −0.65† |
| Hip circumference (cm) | 99.73 ± 1.82 | 0.61† | −0.57† | −0.72† |
| Waist-to-hip ratio | 0.95 ± 0.01 | 0.32 | −0.18 | −0.30 |
| Visfatin | ||||
| Plasma (ng/ml) | 33.58 ± 2.49 | — | — | — |
| CSF (ng/ml) | 3.41 ± 0.12 | −0.36* | — | — |
| CSF-to-plasma ratio | 0.12 ± 0.01 | −0.86† | 0.74† | — |
| Glucose | ||||
| Plasma (mmol/l) | 5.14 ± 0.12 | 0.20 | −0.20 | −0.24 |
| CSF (mmol/l) | 3.31 ± 0.07 | 0.21 | −0.16 | −0.28 |
| CSF-to-plasma ratio | 0.65 ± 0.01 | 0.03 | 0.00 | −0.08 |
| Insulin | ||||
| Plasma (pmol/l) | 84.35 ± 10.56 | 0.23 | −0.32* | −0.33* |
| CSF (pmol/l) | 2.23 ± 0.19 | −0.04 | 0.07 | 0.08 |
| CSF-to-plasma ratio | 0.037 ± 0.004 | −0.24 | 0.28 | 0.31 |
| HOMA | 3.36 ± 0.51 | 0.25 | −0.33* | −0.35* |
| Adiponectin | ||||
| Plasma (μg/ml) | 12.24 ± 0.85 | −0.22 | −0.03 | 0.12 |
| CSF (ng/ml) | 6.02 ± 1.19 | −0.12 | −0.20 | −0.03 |
| CSF-to-plasma ratio | 0.00046 ± 0.00004 | 0.11 | −0.12 | −0.12 |
Plasma levels of visfatin and insulin, CSF insulin concentrations, and HOMA values were log-transformed prior to correlational analyses to achieve normal distribution. n = 38.
*
P < 0.05,
†
P < 0.001,
‡
P < 0.01. CSF, cerebrospinal fluid; HOMA, insulin resistance as calculated by the homeostatic model assessment formula.